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Objective: To compare the effects of combination niacin extended-release + simvastatin 
(NER/S) versus atorvastatin alone on apolipoproteins and lipid fractions in a post hoc analy-
sis from SUPREME, a study which compared the lipid effects of niacin extended-release + 
  simvastatin and atorvastatin in patients with hyperlipidemia or mixed dyslipidemia.
Patients and methods: Patients (n = 137) with dyslipidemia (not previously receiving statin 
therapy or having discontinued any lipid-altering treatment 4–5 weeks prior to the study) received 
NER/S (1000/40 mg/day for four weeks, then 2000/40 mg/day for eight weeks) or atorvastatin 
40 mg/day for 12 weeks. Median percent changes in apolipoprotein (apo) A-1, apo B, and the 
apo B:A-I ratio, and nuclear magnetic resonance lipoprotein subclasses from baseline to week 
12 were compared using the Wilcoxon rank-sum test and Fisher’s exact test.
Results: NER/S treatment produced significantly greater percent changes in apo A-I and apo 
B:A-I, and, at the final visit, apo B , 80 mg/dL was attained by 59% versus 33% of patients, 
compared with atorvastatin treatment (P = 0.003). NER/S treatment resulted in greater percent 
reductions in calculated particle numbers for low-density lipoprotein (LDL, 52% versus 43%; 
P = 0.022), small LDL (55% versus 45%; P = 0.011), very low-density lipoprotein (VLDL) 
and total chylomicrons (63% versus 39%; P , 0.001), and greater increases in particle size 
for LDL (2.7% versus 1.0%; P = 0.007) and VLDL (9.3% versus 0.1%; P , 0.001), compared 
with atorvastatin.
Conclusion: NER/S treatment significantly improved apo A-I levels and the apo B:A-I ratio, 
significantly lowered the number of atherogenic LDL particles and VLDL and chylomicron par-
ticles, and increased the mean size of LDL and VLDL particles, compared with atorvastatin.
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Introduction
Elevated levels of low-density lipoprotein cholesterol (LDL-C) have been shown to 
be directly associated with increased risk for development of atherosclerotic cardio-
vascular disease and related deaths. Current prevention guidelines from the National 
Cholesterol Education Program (NCEP) recommend measurement of LDL-C to esti-
mate lipoprotein-related risks for cardiovascular disease and form the basis of treatment 
recommendations for patients.1 However, recent studies suggest that the quantity and 
size of LDL particles is a better predictor of cardiovascular disease risk and athero-
sclerosis than LDL-C levels,2,3 because patients with the same level of LDL-C may 
have higher or lower numbers of LDL particles, and, as a result, may differ in terms 
of cardiovascular disease risk.4 Because measurement of LDL-C apolipoprotein B 
(apo B) reflects atherogenic lipoprotein burden in serum, multiple US and international   Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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groups now include it in their treatment guidelines, in 
addition to measuring standard lipid levels.5–7
The atherogenicity of LDL particles is influenced by the 
characteristics of various subclasses, which can differ in size, 
density, buoyancy, chemical composition, and physiologic 
behavior.8 Increased levels of small, dense LDL particles are 
associated with increased cardiovascular risk,9,10 whereas an 
inverse relationship exists between large high-density lipo-
protein (HDL) particle levels and cardiovascular disease risk.11 
Therefore, an increased number of small, dense LDL particles 
(LDL subclass pattern B) and decreased concentrations of large 
HDL particles appear to be proatherogenic, while large, buoyant 
LDL particles (LDL subclass pattern A) and increased levels 
of large HDL particles appear to be antiatherogenic.2,3,12 The 
combination of small LDL particles and decreased levels of 
large HDL particles has been termed the atherogenic lipopro-
tein profile.13 Furthermore, studies have shown that increasing 
the levels of apolipoprotein A-I (apo A-I), the major protein 
constituent of HDL cholesterol (HDL-C), is associated with 
decreased cardiovascular risk,14 whereas increased levels of apo 
B are associated with increased   cardiovascular risk.15,16
Niacin has a long-standing history as an effective lipid-alter-
ing therapeutic agent with well established clinical benefits.17–22 
Niacin is the most effective agent marketed for raising HDL-C 
and has also been shown to lower LDL-C, non-HDL-C, 
lipoprotein(a) (Lp(a)), and triglycerides, all factors believed to be 
associated with increased cardiovascular risk.17,19–21 In addition 
to its beneficial effects on standard lipoprotein levels, niacin has 
shown further benefits in patients with coronary artery disease 
by significantly increasing HDL and LDL particle size.22,23
HMG-CoA reductase inhibitors (statins) are commonly 
used for treatment of dyslipidemia and have been shown 
to be the most effective available agents for decreasing 
LDL-C.24–26 In addition, statins have been shown to have 
a variable response in their ability to reduce the number of 
small, dense LDL particles and increase their size.27–29
SUPREME was a study that compared the effects of a once-
daily combination tablet of niacin extended-release (NER, Nias-
pan®, Abbott) and simvastatin (NER/S, Simcor®, Abbott) with 
atorvastatin monotherapy in patients with mixed dyslipidemia.30 
Compared with atorvastatin, combination NER/S treatment 
resulted in superior improvements in HDL-C, triglycerides, and 
Lp(a); both treatments had equivalent responses in lowering 
LDL-C and non-HDL-C.30 We tested the hypothesis that a post 
hoc analysis would show that NER/S compared with atorvastatin 
monotherapy produces additional favorable changes in the levels 
of apo A-1 and apo B, and in the numbers and sizes of LDL and 
very low-density lipoprotein (VLDL) particles.
Methods
study design
SUPREME was a prospective, randomized, open-label, 
blinded-endpoint 12-week Phase IIIB clinical trial conducted 
at clinical centers in the US.30 The study consisted of two peri-
ods, ie, a screening period and a treatment period. The study 
was designed and monitored in accordance with the ethical 
principles of good clinical practice, as required by the major 
regulatory authorities, and in accordance with the Declaration 
of Helsinki. The institutional review board for each study site 
approved the study protocol, and all participants provided writ-
ten informed consent before enrollment.
All patients were instructed to adopt the NCEP Thera-
peutic Lifestyle Changes (TLC) diet for a minimum of four 
weeks during the screening period and to be willing to main-
tain compliance with this diet throughout the study. Patients 
discontinued any pretrial lipid treatments for at least four 
weeks (washout period). Following the four-week TLC diet 
and washout of any pretrial lipid treatments, eligible patients 
were randomized centrally in the ratio of 3:2 to one of two 
treatment regimens (Figure 1): NER/S 1000/40 mg/day for 
four weeks, followed by NER/S 2000/40 mg/day for eight 
weeks, or atorvastatin 40 mg/day alone for 12 weeks.
Inclusion criteria
Patients included men and women aged $ 21 years of age. 
Following compliance with the TLC diet and washout of 
lipid drugs for a minimum of four weeks prior to randomiza-
tion, eligible patients were defined as having primary Type 
II hyperlipidemia or mixed dyslipidemia if their LDL-C 
levels were 130–250 mg/dL, HDL-C , 40 mg/dL for men 
or , 50 mg/dL for women, and triglycerides , 350 mg/dL. 
Baseline fasting lipid measurements for LDL-C and HDL-C, 
drawn at two final screening/washout visits 7 ± 3 days apart, 
were required to be within 15% of each other at the end of 
the screening period.
exclusion criteria
Exclusion criteria included allergy, hypersensitivity, or intol-
erance to niacin, statins, or their derivatives. Women needed 
not to be pregnant or breast-feeding, should not be planning 
to become pregnant or breast-feed, and should be committed 
to using preventative measures against pregnancy. Patients 
should not have used an investigational study medication   
or participated in an investigation within 30 days prior to 
the screening period, taken a prohibited medication within 
four weeks of signing the informed consent form, had active 
gallbladder disease within the preceding 12 months, had Vascular Health and Risk Management 2010:6
Screening +
washout period
(4–5 weeks)  
Randomization
NER/S 1000/40 mg/d
(weeks 1–4) 
NER/S 2000/40 mg/d
(weeks 5–12) 
Atorvastatin 40 mg/d
(weeks 1–12) 
Figure 1 study design.
Abbreviation: neR/s, niacin extended-release/simvastatin.
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chronic pancreatitis or acute pancreatitis within the preceding 
six months, have persistent, uncontrolled hypertension, have 
unstable endocrine diseases, or had poorly controlled Type 1 
or 2 diabetes. Patients with the following laboratory values 
were also excluded: creatine phosphokinase $ 3 × upper limit 
of normal; alanine aminotransferase or aspartate aminotrans-
ferase $ 1.3 × upper limit of normal; calculated creatinine 
clearance , 30 mL/min; glycosylated hemoglobin $ 9%; or 
uric acid levels $ 1.3 × upper limit of normal.
Lipoprotein analyses
Fasting serum levels of apo A-I and apo B were measured by the 
Core Laboratory for Clinical Studies (CLCS, St. Louis, MO) 
using turbidimetric immunoassays, Autokit Apo A1 and Autokit 
Apo B, on a Hitachi 917 analyzer (Wako Chemicals, Richmond, 
VA). Central laboratory services analyzed all clinical laboratory 
samples, including lipids. Samples were collected, distributed, 
processed, and shipped according to the procedures established 
by the CLCS and described in the laboratory manual.
Lipid particle concentration  
and diameter analyses
This was a post hoc analysis of patients who completed 
the study and who had particle size and particle number 
results at baseline and week 12 by the nuclear magnetic 
resonance (NMR) method (LipoProfile Test®, LipoScience 
Inc., Raleigh, NC). Patients’ fasting plasma samples were 
analyzed to determine the diameter (size) and number of 
lipoproteins present by the NMR LipoProfile-II Test®.31–33 
The particle concentrations of the different sized lipoprotein 
subclasses in blood plasma are determined by the   measured 
amplitudes of the characteristic lipid methyl group NMR 
  signals they emit. The subclass signal amplitudes are 
extracted from the composite lipid methyl group signal 
envelope of each plasma sample using a spectral deconvolu-
tion algorithm of particle subspecies actually present in the 
plasma.   Neighboring subpopulations are grouped empirically 
into a smaller number of subclass categories of diameter 
(small, medium, and large) so that the summed amplitudes 
of the individual subpopulation signals give acceptable 
measurement precision (coefficient of variation , 10%). 
  Concentrations of seven subclass categories of diameter are 
reported: intermediate density LDL (IDL, 23–27 nm), large 
LDL (21.2–23 nm), medium small LDL (19.8–21.2 nm), very 
small LDL (18–19.8 nm), large VLDL and chylomicrons 
(. 60 nm), medium VLDL (35–60 nm), and small VLDL 
(27–35 nm). Mean particle diameters (nm) are computed as 
the sum of the diameters of the individual subpopulations 
multiplied by their relative mass percentages, as estimated 
from the amplitudes of their methyl NMR signals.
The shift in lipoprotein profiles of subclass pattern A versus 
subclass pattern B was compared between treatment groups. 
Subclass pattern A is characterized by increased large, buoy-
ant LDL and is also associated with increased HDL particles 
and decreased small LDL particles and triglycerides. Subclass 
pattern B is characterized by the predominance of small, dense, 
atherogenic LDL particles and is also associated with decreased 
HDL-C concentrations and increased triglycerides.
safety
Safety data were collected at each study visit, including the 
last visit. Safety endpoints included the change from baseline 
to each postbaseline visit in safety laboratory parameters and 
vital sign measurements. Safety was also evaluated based on 
data collected for adverse events coded using the Medical 
Dictionary for Regulatory Activities (MedDRA) Version 9.1, 
physical examination findings, pregnancy tests (for women of 
childbearing potential only), and information on flushing.
statistical analyses
Median percent changes in apo A-1, apo B, and the apo 
B:A-I ratio from baseline to week 12 were compared Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1068
Insull et al
between treatment arms by the Wilcoxon rank-sum test. The 
percent changes in LDL-C, HDL-C, non-HDL-C, and total 
cholesterol:HDL-C from baseline to week 12 were compared 
between treatment groups using a repeated-measures mixed 
model, with baseline lipids and site as covariates and treat-
ment as the main factor. The percent changes in triglycerides, 
Lp(a), as well as particle sizes of VLDL and LDL and particle 
numbers of LDL and its subclasses from baseline to week 12 
were compared between treatment groups using the Wilcoxon 
rank-sum test. The proportions of patients with large LDL 
particles at week 12 were compared between treatment groups 
using the Cochran-Mantel-Haenszel method, adjusting for 
the proportion of patients with predominantly large LDL 
particles at baseline. LDL particle size was dichotomized to 
large (20.6–23.0 nm) and small (18.0–20.5 nm) groups.2,3 
The proportion of patients who achieved an LDL particle 
number as defined by apo B , 80 mg/dL (guidelines set by 
the American Diabetes Association34) and an NMR estimated 
particle number of , 1000 nmol/L at week 12 was compared 
between treatment groups using Fisher’s exact test; recent 
treatment guidelines suggest an LDL particle number goal 
of , 1000 nmol/L for high-risk patients.15,35
Results
study population
This was a post hoc analysis of 137 patients (n = 74 for 
NER/S, n = 63 for atorvastatin) from the SUPREME effi-
cacy population (152 patients; n = 82 for NER/S, n = 70 
for atorvastatin) who completed the study and who had 
NMR particle size and particle number results at baseline 
and week 12. This subset was reflective of the total patient 
population from the SUPREME study.30 The characteristics 
of the two treatment groups were reasonably well matched at 
baseline. Baseline demographics and clinical characteristics 
are   summarized in Table 1.
Lipid efficacy
In patients with dyslipidemia, combination NER/S 
2000/40 mg/day treatment resulted in superior improve-
ments,  compared  with  atorvastatin  40  mg/day,  in 
HDL-C (30%   versus 9%; P , 0.001), triglycerides 
(−46% versus −37%; P , 0.05), total cholesterol:HDL-C 
(−47% versus −40%; P , 0.05), and Lp(a), (−18% versus 
+16%; P , 0.001). A subgroup analysis of covariance for 
HDL-C by gender confirmed that NER/S increased HDL-C 
significantly at week 12 compared with atorvastatin in both 
males and females. Additionally, at week 12, more patients in 
the NER/S group achieved the HDL-C target of $ 40 mg/dL 
(males) or 50 mg/dL (females) compared with atorvastatin. 
Specifically, 77.8% of males and 61.7% of females in the 
NER/S group had week 12 HDL-C values equal to or greater 
than their respective targets compared with 18.8% and 19.4% 
of males and females, respectively, in the atorvastatin group 
(P values for both comparisons , 0.0001). There were 
no significant differences between treatment arms in the 
changes in   non-HDL-C and LDL-C (Figure 2).
Apo A-I and Apo B
Baseline serum apolipoprotein levels that were assessed 
  following adherence to a TLC diet and washout of lipid-
  modifying drugs for at least four weeks were typical of 
patients with mixed dyslipidemia (Table 1). At the final 
visit, 59% (44/74) of patients in the NER/S treatment arm 
achieved an apo B , 80 mg/dL in contrast with 33% (21/63) 
of patients in the atorvastatin treatment arm (P = 0.003, 
NER/S versus atorvastatin, Figure 3). NER/S treatment pro-
duced significantly greater improvements in apo A-I and apo 
B:A-I compared with atorvastatin monotherapy (Figure 4) 
when evaluated by percent change from baseline.
Lipid particle number and diameter
Combination NER/S 2000/40 mg/day treatment resulted in 
greater increases in particle diameter for LDL (2.7% versus 
1.0%; P = 0.007) and VLDL (9.3% versus 0.1%; P , 0.001), 
compared with atorvastatin monotherapy (Figure 5). NER/S 
treatment also attenuated the decrease in large LDL, large 
VLDL, and chylomicrons, compared with atorvastatin 
monotherapy (−13% and −45% versus −29% and −53%, 
respectively).
Combination NER/S treatment produced statistically sig-
nificant reductions in atherogenic particle numbers compared 
with atorvastatin 40 mg/day monotherapy, as evidenced by 
median percent changes for total LDL (−52% versus −43%; 
P , 0.05), IDL (−91% versus −66%; P , 0.05), small LDL 
(−55% versus −45%; P , 0.05), and very small LDL (−57% 
versus −45%; P , 0.05, Figure 6A), and VLDL and total 
chylomicrons (−63% versus −39%; P , 0.001), medium 
VLDL (−61% versus −35%; P , 0.05), and small VLDL 
(−61% versus −36%; P , 0.001, Figure 6B). A greater 
proportion of patients in the NER/S group achieved an 
LDL particle   number of less than 1000 nmol/L compared 
with the atorvastatin monotherapy group (46% versus 21%; 
P = 0.002).
In this study, 25% more patients with large, more buoyant 
LDL particles (pattern A, antiatherogenic) were observed at 
week 12 after combination NER/S treatment, compared with Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 1 Demographics and baseline characteristics
Parameter Statistic NER/S 
(n = 74)
Atorvastatin 
(n = 63)
Age (years) Mean (sD) 55.0 (12.5) 51.9 (10.8)
Male n (%) 27 (37) 32 (51)
caucasian n (%) 66 (89) 59 (94)
Weight (kg) Mean (sD) 90.4 (24.2) 88.3 (23.7)
  Women Mean (sD) 86.6 (24.0) 82.0 (23.4)
  Men Mean (sD) 97.1 (23.3) 94.4 (22.7)
BMI (kg/m2)a
 , 18.5 (underweight) n (%) 1 (1) 0 (0)
  18.5–24.9 (normal) n (%) 8 (11) 9 (14)
 $ 25 (overweight) n (%) 18 (24) 27 (43)
 . 30 n (%) 47 (64) 27 (43)
current smoker n (%) 13 (18) 12 (19)
Diabetes mellitus n (%) 14 (19) 7 (11)
Hypertension n (%) 39 (53) 24 (38)
cHD risk categoryb
  0–1 risk factors n (%) 25 (34) 25 (40)
 $ 2 risk factors n (%) 27 (37) 26 (41)
  cHD or cHD risk equivalent n (%) 22 (30) 12 (19)
cHD disease n (%) 6 (8) 2 (3)
concomitant cardiac medications
  Ace inhibitors/ARBs n (%) 23 (31) 14 (22)
  Beta-blockers n (%) 11 (15) 8 (13)
  Aspirin n (%) 22 (30) 16 (25)
Lipids at baseline (mg/dL)
Total-c:HDL-c ratio Mean (sD) 6.1 (1.1) 6.7 (1.4)
non-HDL-c Mean (sD) 199.0 (28.0) 205.8 (31.1)
LDL-c Mean (sD) 162.4 (23.5) 168.0 (29.6)
HDL-c Mean (sD) 39.9 (6.1) 37.6 (6.4)
Tg Median [Q1, Q3] 174.3 [135.5, 222.5] 175.5 [139.5, 235.5]
Lp(a) Median [Q1, Q3] 15.3 [6.5, 30.5] 14.5 [8.0, 41.5]
Apo A-I Median [Q1, Q3] 123.9 [115.9, 134.5] 121.7 [114.3, 131.2]
Apo B Median [Q1, Q3] 130.3 [118.3, 146.9] 133.8 [124.1, 147.2]
Apo B:A-I ratio Median [Q1, Q3] 1.0 [0.95, 1.2] 1.1 [0.98, 1.3]
Notes: aBased on nIH BMI index guidelines; bBased on the NCEP ATP III (2004) definition of risk factors.
Abbreviations: neR/s, niacin extended-release/simvastatin; cHD, coronary heart disease; Ace, angiotensin converting enzyme; ARB, angiotensin receptor blocker; 
sD, standard deviation; [Q1, Q3], [25th percentile, 75th percentile]; nIH, national Institutes of Health; BMI, body mass index; nceP ATP, national cholesterol education 
Program Adult Treatment Panel; total-c, Total cholesterol; HDL-c, high-density lipoprotein cholesterol; non-HDL-c, non-high-density lipoprotein cholesterol; LDL-c,     
low-density lipoprotein cholesterol; Tg, triglycerides; Lp(a), lipoprotein(a); Apo, apolipoprotein.
atorvastatin monotherapy (69% versus 44%; P = 0.005, based 
on Cochran-Mantel-Haenszel test, Figure 7).
safety
Safety analyses included only results from patients used for this 
post hoc analysis. Overall, NER/S treatment and atorvastatin 
monotherapy were consistent with the established profiles of 
these medications (Table 2) and that reported for the overall 
population from the SUPREME study.30 Eighty-two percent of 
patients in the NER/S group and 41% of patients in the ator-
vastatin group experienced treatment-emergent adverse events, 
defined as those events with onset dates that were on or after 
the study medication start dates (P , 0.001, Fisher’s exact test); 
the adverse event of flushing primarily accounted for the higher 
percentage of patients in the NER/S group. A full detailed 
account of the safety results from the entire patient population 
can be found in the original SUPREME publication.30
Discussion
The focus of lipid-altering therapies has been largely on 
their abilities to lower LDL-C and triglyceride levels and 
raise HDL-C levels. This study demonstrates that in addi-
tion to these effects, combination NER/S treatment also 
provides additional significant benefit above atorvastatin 
monotherapy treatment in numerous measures of the 
atherogenic lipoprotein profile. Treatment with combination 
NER/S 2000/40 mg/day produced superior improvements in 
HDL-C, triglycerides, and Lp(a), compared with atorvastatin Vascular Health and Risk Management 2010:6
−70
−60
−50
−40
−30
−20
−10
0
10
20
30
Apo B
M
e
d
i
a
n
 
p
e
r
c
e
n
t
 
c
h
a
n
g
e
f
r
o
m
 
b
a
s
e
l
i
n
e
 
Atorvastatin
NER/S
**
*
−38.5 −44.2 −38.8 −48.2 1.41 0.1
Baseline, mg/dL:
Atorvastatin
NER/S 130.3
133.8
123.9
121.7
1.0
1.1
Apo B:A-1 ratio Apo A-1
Figure 4 Median percent change in Apo A-1, Apo B, and the Apo B:A-I ratio at final 
visit. error bars are [Q1, Q3].
Notes: *P , 0.01, **P , 0.001 versus atorvastatin, Wilcoxon rank-sum test. 
Abbreviations: neR/s, niacin extended-release/simvastatin; Apo, apolipoprotein.
Total-C:HDL Baseline, mg/dL:
6.1
Atorvastatin
NER/S
6.7 14.5
15.3
175.5 37.6
39.9 174.3
175.5
199.0 162.4
168.0 205.8
**
*
*
**
−40.4
8.7 16.3
−47.1
30.2
−80
−60
−40
−20
0
20
40
C
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
,
 
%
Atorvastatin
NER/S
Non-HDL-C LDL-C HDL-C TG Lp(a)
−46.5 −36.5 −43.7 −45.9 −45.8 −45.6 −17.6
Figure 2 Lipid efficacy from baseline to week 12. For total-C:HDL, non-HDL-C, LDL-C and HDL-C: Bars represent least square means, error bars are standard errors; For 
Tg and Lp(a): Bars represent medians, error bars are [Q1, Q3].
Notes: *P = 0.05; **P , 0.001; repeated measures of covariance (AncOVA) for total HDL-c, non-HDL-c, LDL-c, and HDL-c; Wilcoxon rank-sum test for Tg and Lp(a). 
Abbreviations:  Total-c,  total  cholesterol;  HDL-c,  high-density  lipoprotein  cholesterol;  non-HDL-c,  non-high-density  lipoprotein  cholesterol;  LDL-c,  low-density 
lipoprotein cholesterol; Tg, triglycerides; Lp(a), lipoprotein(a); neR/s, niacin extended-release/simvastatin; [Q1, Q3], [25th percentile, 75th percentile].
0
10
20
30
40
50
60
70
Week 12
P
e
r
c
e
n
t
 
o
f
 
p
a
t
i
e
n
t
s
Atorvastatin
NER/S *
33.0
59.0
Figure 3 Percent of patients who attained Apo B , 80 mg/dL at week 12.
Note: *P = 0.003 versus atorvastatin, Fisher’s exact test.
Abbreviations: neR/s, niacin extended-release/simvastatin; Apo, apolipoprotein.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1070
Insull et al
40 mg/day monotherapy, and additionally resulted in sig-
nificant improvement in LDL particle number and preva-
lence of small LDL particles. Following just 12 weeks of 
treatment, NER/S significantly decreased total numbers of 
atherogenic LDL, VLDL, and chylomicron particles, and 
increased the mean diameter of LDL and VLDL particles. 
NER/S treatment also significantly shifted the lipoprotein 
profile towards subclass pattern A, consisting of large, buoy-
ant LDL, whereas this shift did not occur after 12 weeks of 
atorvastatin monotherapy. Lastly, greater improvements in 
apo B, apo A-I, and apo B:A-I were observed with NER/S 
treatment compared with atorvastatin monotherapy. Thus, 
different lipid agents appeared to cause substantially different 
quantitative and qualitative effects on lipoproteins, beyond 
the conventionally measured responses observed in serum 
lipid subfractions.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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The number and size of circulating lipid particles, in 
addition to the total level of cholesterol, are increasingly 
recognized as important for better assessment of cardiovas-
cular risk.5,36–38 The size and number of lipid particles may 
be a better predictor of cardiovascular risk than LDL-C. 
Patients with the same levels of LDL-C may have substan-
tially different LDL particle numbers and size distribution, 
and hence may be different in terms of cardiovascular risk, 
ie, those with greater LDL particle numbers, or smaller 
LDL size, incurring a greater risk for a cardiovascular 
event.4 Thus, favorable changes in lipoprotein number, 
size, and composition may all contribute to the reduction 
in cardiovascular risk.
The apo B content of the lipid profile can also differ 
substantially in response to interventions, because this mea-
surement provides an estimate of atherogenic (non-HDL) 
particle number because apo B is present at a fixed ratio of 
one molecule per particle and does not exchange between 
particles as the other apolipoproteins do. Several studies, 
including AMORIS (Apolipoprotein-related Mortality Risk)39 
and 4S (Scandinavian Simvastatin Survival Study),40 have 
shown that apo B is a significant predictor of cardiovascular 
events, and this measurement is now often used to provide 
a measure of LDL or non-HDL particle concentration.41 In 
addition, therapies that result in lowering apo B levels can 
translate into lower risk of cardiovascular disease.42–44
Several studies have shown that LDL particle levels 
are consistently more predictive of cardiovascular events 
compared with other lipid parameters, including VA-HIT 
(Veterans Affairs High-Density Lipoprotein Cholesterol 
Intervention Trial),10 the Women’s Health Study,45,46 and the 
Framingham Heart Study.47,48 The Framingham Heart Study 
also demonstrated that cardiovascular event rates among 
patients with low LDL particle numbers were significantly 
reduced in contrast with patients having low LDL-C,47 sug-
gesting that cardiovascular risk is in part mediated by LDL 
particle burden, as well as particle composition.
The benefits of combination lipid-modifying agents 
on lipid particle size and number have not been well 
characterized until recently, although the modification 
of complementary lipid pathways may be advantageous 
beyond conventional statin monotherapy. Niacin has a 
long history as a pleiotropic lipid therapy; in particular, it 
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is the most effective agent marketed for raising HDL-C, 
while also improving LDL-C and triglyceride levels.17,19–21 
NER decreases atherogenic, small, dense LDL and VLDL 
particles, while increasing levels of large HDL subclasses 
in patients with primary   hypercholesterolemia.49 Several 
studies have   examined the effects of NER on LDL particle 
number and density in patients with stable coronary artery 
disease who were already treated at baseline with a statin 
to an NCEP LDL-C goal of ,100 mg/mL.22,49,50 Jafri et al50 
found that after three months of NER treatment, the mean 
number of medium and small LDL particles was significantly 
decreased in patients with stable coronary artery disease 
compared with placebo-treated patients. Furthermore, 
NER favorably altered the mean number of HDL particles 
typically associated with an atherogenic profile, decreasing 
the small HDL particles and increasing the large HDL par-
ticles.50 Kuvin et al22 found that NER treatment in patients 
with stable coronary artery disease significantly increased 
both HDL and LDL particle size. Superko et al23 reported 
that NER monotherapy favorably shifted LDL particle size 
and distribution, with a greater increase in mean LDL peak 
particle diameter and larger reductions in the proportions of 
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Figure 7 shift in LDL particle size from baseline to week 12. error bars are 95% 
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Notes: *P = 0.005 versus atorvastatin based on cochran-Mantel-Haenszel test. 
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Table 2 summary of adverse events
NER/S 
n = 74
Atorvastatin 
n = 63
P valuea
Patients, n (%)
Any TeAeb 61 (82.4) 26 (41.3) ,0.001
Any Ae possibly drug-relatedc 52 (70.3) 9 (14.3) ,0.001
Any serious Aed 2 (2.7) 1 (1.6) 1.000
TeAes in order of frequency occurring in $5% of patients in either 
treatment group, n (%)
Flushing 49 (66.2) 7 (11.1) ,0.001
nausea 7 (9.5) 0 (0.0) 0.015
Vomiting 6 (8.1) 0 (0.0) 0.031
Diarrhea 5 (6.8) 1 (1.6) 0.218
Headache 5 (6.8) 1 (1.6) 0.218
constipation 5 (6.8) 0 (0.0) 0.062
Notes:  aP values are based on Fisher’s exact test;  bincluding flushing;  cpossible, 
probable, or definite relationship to treatment based on investigator assessment; 
da serious adverse event is defined as any untoward medical occurrence that at 
any dose results in death, is life-threatening, requires inpatient or prolongation of 
existing hospitalization, results in persistent or significant disability/incapacity, is a 
congenital anomaly/birth defect, is a medically important event or reaction that may 
not be immediately life-threatening or results in death or hospitalization, but may 
jeopardize the patient or require intervention to prevent any of the other outcomes 
listed above.
Abbreviations:  neR/s,  niacin  extended-release/simvastatin;  TeAe,  treatment-
emergent adverse event; Ae, adverse event.
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smaller LDL subclasses in patients exhibiting the atherogenic 
LDL subclass pattern B. These findings, in the context of the 
results of the present study, are congruent with the further 
reduction of cardiovascular risk with the addition of niacin 
to background therapy, even in patients whose cholesterol 
levels were managed to NCEP goals.
The findings of this study, in favorably modifying the 
lipoprotein profile, including lipid particle diameter and 
number, over that of statin monotherapy, are clinically 
pertinent, because the small, dense LDL subfractions are 
associated with atherosclerotic burden and progression, 
measured either early, by magnetic resonance imaging or 
ultrasound as carotid intima-media thickness, or later, by 
arteriography as arterial plaque.51,52
Because atherosclerotic development and progression 
spans a pathologic and temporal spectrum,53 there is con-
siderable potential for this combination therapy to impact 
the process over a cross-section of patients. In a healthy 
community-based population, Norata et al54 correlated carotid 
intima-media thickness with an atherogenic lipoprotein 
  pattern, providing further evidence to consider measure-
ments supplementary to conventional cholesterol fractions 
in   discerning cardiovascular risk.
Notably, niacin-based regimens have demonstrated regres-
sion of the atherosclerosis process with the different imaging 
modalities, vide supra, in contrast with statin monotherapies, 
which, at best, have shown only delayed progression.55–57 
This has been observed by Taylor et al58,59 and most recently 
by Lee et al.60 Consonant with these results from adding 
niacin to background therapy,   Airan-Javia et al61 found over 
12 months that the coadministration of NER 2000 mg/day 
plus simvastatin 20 mg/day produced a greater reduction 
in the proportion of patients with small, atherogenic LDL 
pattern B, compared with patients treated with simvastatin 
20 mg or 80 mg monotherapy.
The mechanistic bases of how these modifications in 
the lipoprotein subfractions affect atherosclerosis has not 
been defined, although the contribution of these fractions to 
endothelial dysfunction16 and inflammation54 has been noted. 
With a combination therapy that produces improvements in 
the lipoprotein profile and lipid particle size and number, this 
study provides a basis for generating testable hypotheses of 
the interaction of these fractions with the artery wall in the 
development of atherosclerotic plaques.
Accumulating evidence demonstrates that the com-
bination of NER with simvastatin also favorably modu-
lates inflammatory pathways. Kuvin et al22 showed that 
NER/S decreases high-sensitivity C-reactive protein 
(hsCRP)   levels, while significantly increasing HDL and 
LDL particle size, consistent with the salutary effects of 
niacin. A post hoc analysis from OCEANS (Open-Label 
Evaluation of the Safety and Efficacy of a Combination 
of Niacin ER and SimvAstatin)62 confirmed that treatment 
with NER/S significantly decreased hsCRP levels beyond 
statin monotherapy in patients with elevated baseline 
hsCRP $ 2 mg/L (−34.6%; P , 0.005 versus baseline).63 
Overall, the combined NER/S treatment has the potential 
for improved reduction of residual risk of coronary heart 
disease after statin monotherapy.
The safety profile of combination NER/S therapy in 
this trial was commensurate with those of the individual 
medications, in light of the faster dose escalation regi-
men with NER/S or atorvastatin in the SUPREME study. 
There are limitations to this study, including a small patient 
population and a relatively short study duration. However, 
12 weeks was sufficient for NER/S to improve the lipid 
profile and lipoprotein subclass distributions significantly, 
consistent with previous reports. Given these limitations, 
the cardiovascular event rates were not different between 
treatments. However, this relationship will be defined by 
AIM HIGH (Atherosclerosis Intervention in Metabolic 
syndrome with low HDL-C High triglyceride and Impact on 
Global Health outcomes), which is evaluating cardiovascular 
events in approximately 3300 patients treated with NER/S 
or   simvastatin monotherapy.
Conclusion
NER/S 2000/40 mg/day compared with atorvastatin 40 mg/day 
monotherapy provided superior improvements in HDL-C, 
Lp(a), and triglycerides, and comparable improvements in 
non-HDL-C and LDL-C. NER/S compared with atorvastatin 
monotherapy, also produced a shift towards a less atherogenic 
profile of lipoproteins, based on particle diameter and number, 
although both regimens achieved similar improvements in 
total LDL-C levels. This improvement was accompanied by 
increased apo A-I levels and a reduction in the apo B:A-I ratio. 
These results are consistent with previously noted improve-
ments in atherosclerosis observed with various imaging 
modalities, suggesting that combination NER/S treatment may 
potentially further decrease cardio  vascular risk in patients with 
dyslipidemia beyond that achieved by statin monotherapy.
This study has several major novel features that warrant 
comment. First, the study adds to our scientific knowledge 
about effects of treatment upon LDL particle metabolism. 
It is the first report of a controlled clinical trial comparing 
NER/S versus atorvastatin for effects upon the particles of the Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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lipoproteins containing apoB, and their numbers and sizes. 
Finally, the study demonstrated substantial advantages of 
NER/S over atorvastatin with regard to the greater efficacy of 
the combination for reducing small particles and increasing 
large particles in LDL-C, presumably resulting in a greater 
reduction of cardiovascular disease risk.
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